RE:RE:Perplexity Ai's expectations for pediatric trial resultsAre these valid expectations?
The pediatric trial compares
macimorelin to clonidine and arginine. Here's what Perplexity Ai says including the other tests: Given this data, we can refine our expectations for the Phase 3 DETECT trial: - Sensitivity: 95-100%
- Specificity: 80-90%
- ROC AUC: 0.90-0.95
- Clonidine:
Clonidine stimulation test generally has lower accuracy compared to other GH stimulation tests:
- Sensitivity: 70-85%
- Specificity: 85-95%
The lower performance is partly due to the fact that many normal individuals may have no detectable GH response or show the same response as to placebo. - Arginine:
The arginine stimulation test typically performs better than clonidine but may not be as accurate as macimorelin:
- Sensitivity: 80-90%
- Specificity: 90-95%
It's important to note that the actual performance may vary in the pediatric population. The combination of multiple tests (2 macimorelin, 1 clonidine, and 1 arginine) in this study design will likely provide a comprehensive assessment of each test's performance in children.The macimorelin test is expected to outperform both clonidine and arginine tests in terms of sensitivity and specificity. Its oral administration and the shorter duration of the test (5 blood samples over a shorter period compared to 4 samples for clonidine and arginine) may also contribute to better patient tolerability, especially in children.The study's design, including multiple visits and different stimulation tests, will allow for a thorough comparison of these diagnostic methods in the pediatric population. This comprehensive approach should provide robust data on the relative performance of macimorelin compared to the established tests, potentially supporting its use as a preferred diagnostic tool for pediatric GHD if it demonstrates superior accuracy and tolerability.